Abstract Details

Title Predictors of cerebral tauopathy in individuals with normal cognition and amnestic mild cognitive impairment (aMCI): results from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) Aging and Dementia Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 049

Objective To identify predictive features of tauopathy defined by PET imaging across the AD spectrum.

Background

The time course of tau aggregation and its dynamic relationship to other pathophysiological features in the various stages of AD is incompletely characterized.

Design/Methods We selected 508 cognitively unimpaired elderly and 213 participants with aMCI and 31 individuals with dementia (AD) from ADNI. Participants were classified as having normal (T−) or abnormal (T+) tau using the cutoff point of standard uptake value ratio (SUVr) 1.40 in the tau meta-ROI (entorhinal, amygdala, parahippocampal, fusiform, inferior temporal, and middle-temporal-ROIs normalized to cerebellar-crus). Stepwise multivariate logistic regression was carried out to identify predictors of tau positivity for the whole population, and CN and aMCI subgroups, first using demographic, clinical and genetic features and then adding imaging features.

Results Positive tau PET scans were detected in 7.9% of CN, 26.8% of aMCI, and 67.7% of AD individuals. In the entire sample, predictors of tau positivity included at least one ApOE4 allele, clinical dementia rating sum of boxes (CDR-SB), Alzheimer Disease Assessment Scale–cognitive subscale (ADAS-cog). Imaging biomarkers improving prediction included hippocampal volume and Aβ positivity on PET. Predictors of tauopathy were different for each diagnostic subgroup: Among CN individuals age and CDR-SB were predictors of tauopathy and of the imaging markers only Aβ PET contributed significantly. In the aMCI group, APOE4, ADAS-cog, and logical memory were predictors of tau positivity with incremental prediction from hippocampal volume, and Aβ burden.

Conclusions

Aβ positivity seems to precede substantial tau deposition and is the main predictor of tau positivity across the AD spectrum. Neurocognitive scores, APOE4 alleles, and neurodegeneration biomarkers may help with the identification of tau positive individuals in later stages of disease.

Authors/Disclosures
Ali Ezzati, MD (University of California, Irvine) PRESENTER	The institution of Dr. Ezzati has received research support from NIA. The institution of Dr. Ezzati has received research support from Alzheimer's Association. The institution of Dr. Ezzati has received research support from Cure Alzheimer's Fund.
	No disclosure on file
Kellen Petersen (Albert Einstein College of Medicine)	No disclosure on file
Richard B. Lipton, MD, F�鶹��ýӳ�� (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.

�鶹��ýӳ��

�鶹��ýӳ��